Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.

This is a large phase 3 double-blind randomized controlled trial, the strongest tier of clinical evidence for retatrutide in type 2 diabetes. All three doses were associated with significantly greater HbA1c and weight reductions versus placebo, and the safety profile matched other GLP-1-class agents. Two deaths occurred, both reported as unrelated to the study drug; the trial was funded by the manufacturer.